Novel Endocrine Therapies: Current Status and Future Directions.

Authors

Elena Brierley-Green, Niharika Duggirala, Kelly E McCann, Rena Callahan, Aditya Bardia, Marla Lipsyc-Sharf

Published in

Clinical breast cancer. Volume 26. Issue 9. Pages 127-136. Aug 22, 2026. Epub Aug 22, 2026.

Abstract

Recent advances in endocrine therapy have led to the development of novel oral agents that target estrogen receptor signaling in estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer. This review outlines key findings from clinical trials of Food and Drug Administration (FDA)-approved selective estrogen receptor degraders (SERDS), including elacestrant and imlunestrant, the newly FDA-approved proteolysis-targeting chimera (PROTAC) vepdegestrant, as well as emerging oral SERDs, PROTACs, complete estrogen receptor antagonists, selective estrogen receptor covalent antagonists (SERCAs), and other targeted therapies. We explore their mechanisms, efficacy, tolerability, and potential to improve treatment options and outcomes in both metastatic and early-stage disease.

PMID:
42632230
Bibliographic data and abstract were imported from PubMed on 23 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.